Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has completed the second phase of a $5.5 million expansion programme at its Kansas City, Missouri facility, to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
This marks the conclusion of a 2 year project that has also expanded the facility’s highly-potent, cytotoxic and cold storage clinical drug packaging capabilities.
The latest expansion includes a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault, providing the site with an additional 3600 sq ft. of storage, as well as additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations.
A new sampling room has been installed, as well as a new emergency generator to ensure the security and integrity of samples in storage.
“Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years,” said Kevin Economos, General Manager of Clinical Supply Services at the site.
“The latest expansions are critical enablers to our customers’ continued growth that reinforce our comprehensive global network and enhance Catalent’s role as a market leader in the clinical supply industry.”
Catalent’s 450,000 sq ft. Kansas City facility provides a range of fully integrated support services, from development and analytical support through to packaging and distribution.
The expansions at Kansas City follow the recent announcements of new capabilities and capacity at two of Catalent’s other clinical supply facilities in Philadelphia and Singapore.
With sites in the US, UK, Germany, Singapore, Japan and China, and an extended network of more than 50 depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, helping to expedite clinical trials by ensuring customers are reliably supplied where and when needed around the globe.
